FDA Approves Teplizumab for Children With Stage 3 Type 1 Diabetes – Despite Delays & Controversy

The U.S. Food and Drug Administration approved Sanofi’s drug teplizumab on June 13, 2026, for children aged 8 and older with stage 3 type 1 diabetes. According to STAT, the approval followed a contentious review process marked by missed deadlines and internal disagreements between FDA staff and senior agency leadership.

Teplizumab is designed to delay the onset of clinical type 1 diabetes in patients who show biological markers of the disease but have not yet developed full symptoms. The drug targets the immune system to slow the destruction of insulin-producing beta cells in the pancreas.

How does teplizumab treat stage 3 diabetes?

Stage 3 type 1 diabetes is a pre-symptomatic phase where a patient possesses two or more diabetes-related autoantibodies and exhibits abnormal glucose tolerance, according to clinical guidelines from the National Institutes of Health. While these patients do not yet require insulin, they are at high risk of progressing to clinical diabetes.

Teplizumab acts as an anti-CD3 monoclonal antibody. It binds to the CD3 receptor on T-cells, which are the immune cells responsible for attacking the pancreas. By modulating these T-cells, the drug can extend the period of time a patient remains in stage 3 before progressing to stage 4, where insulin dependence begins.

The FDA’s approval on June 13, 2026, specifically extends this treatment option to children as young as 8 years old who meet the stage 3 criteria.

Why was the FDA approval process delayed?

The drug was enrolled in a speedy review program established last year by former FDA Commissioner Marty Makary. However, the agency failed to meet its official goal date of April 21, 2026, to deliver a final decision, according to STAT.

The delay stemmed from an internal conflict regarding the scientific review. STAT reported that former top drug regulator Tracy Beth Høeg disagreed with a staff decision to approve the medication. This disagreement led Sanofi to request the removal of teplizumab from the expedited review program.

The intervention by Høeg is noted as unusual because center directors, particularly political appointees, rarely involve themselves in individual scientific reviews of specific drugs.

What are the implications for pediatric diabetes care?

The ability to treat type 1 diabetes before the onset of clinical symptoms represents a shift in how the disease is managed. Traditionally, treatment only began after the destruction of beta cells reached a point where the body could no longer regulate blood sugar, leading to the risk of diabetic ketoacidosis.

By intervening at stage 3, clinicians can potentially push back the need for daily insulin injections and glucose monitoring. This window of opportunity depends on early screening, as most patients are unaware they are in stage 3 until they undergo specific autoantibody testing.

Medical context for the drug’s utility includes the following factors:

• Beta-cell preservation: The drug aims to keep more insulin-producing cells functional for a longer period.
• Symptom delay: Delaying the transition to stage 4 reduces the immediate psychological and physical burden of diabetes management in young children.
• Screening necessity: The drug’s effectiveness requires the identification of stage 3 patients via blood tests for autoantibodies.

What happens next for Sanofi and the FDA?

Following the June 13, 2026, approval, Sanofi will move toward distributing the drug for the pediatric population. The company’s previous request to pull the drug from the expedited program was rendered moot by the final approval.

The FDA has not issued a separate statement regarding the internal disagreements reported by STAT or the missed April 21 deadline. The agency’s focus remains on the safety and efficacy data that ultimately supported the approval for children aged 8 and older.